Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients

Heart and Vessels

Volumn 26, Issue 4, 2011, Pages 408-413

  Miyoshi, Toru ^a   Doi, Masayuki ^b   Hirohata, Satoshi ^a   Kamikawa, Shigeshi ^a   Usui, Shinichi ^c   Ogawa, Hiroko ^a   Sakane, Kosuke ^b   Izumi, Reishi ^c   Ninomiya, Yoshifumi ^a   Kusachi, Shozo ^c  

^a OKAYAMA UNIVERSITY   (Japan)

^b Sumitomo Besshi Hospital   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adipocyte; angiotensin II receptor antagonist; atherosclerosis; fatty acid; hypertension; inflammation

Indexed keywords

C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN 4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; TRIACYLGLYCEROL;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE AGENTS; ARTERIES; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; DOWN-REGULATION; ELASTICITY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051471966     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-010-0060-x     Document Type: Article

References (34)

1. Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442-2450 (Pubitemid 36993340)
2. Oda E (2008) The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 31:1283-1291
3. Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR (2005) Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 25:1220-1224 (Pubitemid 40776612)
4. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377-1379 (Pubitemid 26391462)
5. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7:699-705 (Pubitemid 32588026)
6. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52:405-413
7. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS (2007) Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 30:2667-2672 (Pubitemid 47547818)
8. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS (2007) Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 27:1796-1802 (Pubitemid 47207176)
9. Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, Sung KC, Kim BS (2009) The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 160:165-172
10. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, Ninomiya Y (2010) Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 211:164-169
11. Lind L, Berne C, Lithell H (1995) Prevalence of insulin resistance in essential hypertension. J Hypertens 13:1457-1462 (Pubitemid 26015762)
12. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV (2005) Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112: 48-53 (Pubitemid 40962568)
13. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S (2002) Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J Hypertens 20: 1879-1886
14. Julius S, Kjeldsen SE,Weber M, Brunner HR, Ekman S,Hansson L, HuaT,Laragh J,McInnesGT,MitchellL, Plat F,SchorkA,Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022-2031 (Pubitemid 38781102)
15. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 3:283-291 (see pp 318
16. Smith DH, Dubiel R, Jones M (2005) Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 5:41-50
17. Fliser D, Buchholz K, Haller H (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110:1103-1107 (Pubitemid 39319009)
18. Futai R, Ito T, Kawanishi Y, Terasaki F, Kitaura Y (2009) Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. Heart Vessels 24:294-300
19. Ogihara T, Kikuchi K,Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim- Mitsuyama S,KimuraG,Matsubara H,Matsuura H,NaruseM, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, RakugiH (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32:3-107
20. (1997) World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 35:2-3
21. Miyoshi T, Hirohata S, Uesugi T, Hirota M, Ohnishi H, Nogami K, Hatanaka K, Ogawa H, Usui S, Kusachi S (2009) Relationship between activin A level and infarct size in patients with acute myocardial infarction undergoing successful primary coronary intervention. Clin Chim Acta 401:3-7
22. Koten K, Hirohata S, Miyoshi T, Ogawa H, Usui S, Shinohata R, Iwamoto M, Kitawaki T, Kusachi S, Sakaguchi K, Ohe T (2008) Serum interferon-gamma- inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clin Biochem 41:30-37 (Pubitemid 350216829)
23. Shirai K, Utino J, Otsuka K, Takata M (2006) A novel blood pressure-independent arterial wall stiffness parameter; cardioankle vascular index (CAVI). J Atheroscler Thromb 13:101-107
24. Sakane K, Miyoshi T, Doi M, Hirohata S, Kaji Y, Kamikawa S, Ogawa H, Hatanaka K, Kitawaki T, Kusachi S, Yamamoto K (2008) Association of new arterial stiffness parameter, the cardioankle vascular index, with left ventricular diastolic function. J Atheroscler Thromb 15:261-268
25. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI (1995) Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 26:485-490
26. Kadota K, Takamura N,Aoyagi K,Yamasaki H, UsaT,NakazatoM, Maeda T, Wada M, Nakashima K, Abe K, Takeshima F, Ozono Y (2008) Availability of cardio-ankle vascular index (CAVI) as a screening tool for atherosclerosis. Circ J 72:304-308 (Pubitemid 351413373)
27. Fernandes-Santos C, de Souza Mendonca L, Mandarimde-Lacerda CA (2009) Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. Heart Vessels 24:219-227
28. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296-1301
29. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF (2006) Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45:154-162 (Pubitemid 44716729)
30. Boord JB, Fazio S, Linton MF (2002) Cytoplasmic fatty acidbinding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 13:141-147 (Pubitemid 34280765)
31. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L (2007) Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195:e150-e158 (Pubitemid 47569987)
32. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, Namikoshi T, Arakawa S, Tomita N, Kashihara N (2008) Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 31:305-313 (Pubitemid 351461111)
33. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak CJ, Nakano D, Sohmiya K, Okada Y, Kitaura Y, MatsumuraY(2007) Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxiainduced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 30:1219-1230 (Pubitemid 351176420)
34. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS (2005) The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 280:12888-12895